GATA6 Amplification Is Associated With Improved Survival in TP53-Mutated Unresectable Pancreatic Cancer
We found that GATA6 amplification appeared to attenuate poor prognosis observed in TP53-mutant patients regardless of the type of standard chemotherapy received, suggesting the GATA6 amplification is a prognostic biomarker but not a predictive biomarker of standard-of-care chemotherapy.
Authors
- Jeff Boyd (ORCID: https://orcid.org/0000-0002-3517-7637)
- Astrid Deschênes (ORCID: https://orcid.org/0000-0001-7846-6749)
- Christopher Hollweg (ORCID: https://orcid.org/0000-0002-1109-5004)
- Taehoon Ha (ORCID: https://orcid.org/0000-0002-4533-1140)
- Amber N. Habowski (ORCID: https://orcid.org/0000-0003-1107-3208)
- Chris Tzanavaris
- Daniel A. King (ORCID: https://orcid.org/0000-0001-6451-712X)
- Pascal Belleau
- Jung‐In Yang (ORCID: https://orcid.org/0000-0003-0685-355X)
- David A. Tuveson (ORCID: https://orcid.org/0000-0002-8017-2712)
- Edward Zhou (ORCID: https://orcid.org/0000-0003-0914-1523)
- Xinhua Zhu (ORCID: https://orcid.org/0000-0002-3801-6329)
Institutions
- Northwell Health (US)
- Cold Spring Harbor Laboratory (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
Publication Details
- Journal
- Pancreas
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1097/mpa.0000000000002431
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00